Chronic Inflammatory Skin Diseases and Shingles Risk

September 03, 2020

Study suggests higher hospitalization rate for some skin diseases.

FDA Approves Dupilumab for Atopic Dermatitis in Children

May 26, 2020

Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.

Phase 3 Study: Apremilast Shows Efficacy in Mild-to-Moderate Plaque Psoriasis

May 08, 2020

Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.

FDA OKs Crisaborole for Use in Children as Young as 3 Months of Age

March 24, 2020

Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.

Abrocitinib Improves Moderate-to-Severe Atopic Dermatitis in Phase 3 Study

March 23, 2020

Phase 3 clinical data demonstrate abrocitinib’s efficacy and safety in treating moderate-to-severe atopic dermatitis in adults.

New Phase 3 Data on Baricitinib Efficacy in Atopic Dermatitis

February 04, 2020

Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.

FDA Grants Priority Review to Dupilumab for Children with Atopic Dermatitis

January 28, 2020

If approved, dupilumab (Dupixent, Regeneron and Sanofi) would be indicated for use as an add-on maintenance treatment for children ages 6 to 11 years with moderate-to-severe atopic dermatitis.

What Pharmacists Need to Know About Psoriasis Medications

January 17, 2020

Pharmacists can play an integral role in managing patients with psoriasis through medication therapies and lifestyle modifications. 

Minocycline Topical Foam 4% Approved by FDA for Acne Vulgaris

October 21, 2019

Available for prescribing starting January 2020

Cetirizine IV Approved for Pediatric Acute Urticaria

October 18, 2019

Originally approved in 1995 for use in adults only.